Human Recombinant Insulin Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Human Recombinant Insulin Market Analysis | CMI

Description:

Read here the latest updates on the Human Recombinant Insulin Market published by CMI team – PowerPoint PPT presentation

Number of Views:1

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Human Recombinant Insulin Market Analysis | CMI


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
HUMAN RECOMBINANT INSULIN MARKET ANALYSIS
  • Human Recombinant Insulin Market, by Product Type
    (Rapid-Acting Human Insulin, Short-Acting Human
    Insulin, Intermediate-Acting Human Insulin,
    Long-Acting Human Insulin, and Premixed Human
    Insulin), by Brand (Humalog, Novolog, Apidra,
    Humulin R, Novolin R, Humulin N, Novolin N,
    Levemir, Lantus, Humalog Mix, Novolog Mix, and
    Others), By Distribution Channel (Hospital
    Pharmacies, Retail Pharmacies, and Online
    Pharmacies), and by Region - Global Forecast to
    2026
  • The global human recombinant insulin market was
    valued at US 27.4 billion in 2018, and is
    expected to witness a CAGR of 7.2 over the
    forecast period (2018 2026).

3
Figure 1 Global Human Recombinant Insulin Market
Share, By Product Type
4
Market Drivers
  • Increasing Investment in Diabetes Research
    Activities is expected to Boost the Growth of
    Human Recombinant Insulin Market
  • Various government and private research
    organizations are engaged research and
    development activities for developing advanced
    treatment in diabetes care to increase the
    effectiveness of human insulin, reduce diabetes
    burden, and minimize the risk of diabetes
    associated disorders such as diabetes-associated
    blindness, kidney disease, heart attacks, strokes
    or limb loss. For instance, American Diabetes
    Association (ADA) invested US 807.4 million in
    more than 4,700 research projects in diabetes
    research since 1952 till 2017. According to ADA,
    2017 review, ADA invested more than US 37.4
    million for diabetes research in 2017, and
    supported 371 diabetes related research projects.
    The European Foundation for the Study of Diabetes
    (EFSD) a division of European Association for
    the Study of Diabetes (EASD), provides funding
    initiatives in all areas of diabetes research.
    EFSD aims to accelerates and support research in
    the field of diabetes to introduce innovative
    diabetic management portfolio.
  • In September 2017, Biocon Limited an India-based
    biopharmaceutical firm received funding from
    Juvenile Diabetes Research Foundation (JDRF) to
    study oral insulin drug candidate Tregopil, to
    evaluate the safety and tolerability in people
    suffering with type 1 diabetes. The collaboration
    between Biocon and JDRF is a part of JDRF's
    Industry Discovery and Development Partnership
    (IDDP) programme, through which JDRF provides
    financial support to Biocon to accelerate
    research in type 1 diabetes management.

5
  • Increasing Incidence of Diabetes Worldwide is
    expected to Drive Growth of the Human Recombinant
    Insulin Market
  • Insulin plays a vital role in diabetes management
    by controlling blood sugar level. Both type 1 and
    type 2 diabetes people are benefited by
    maintaining blood sugar levels. Increasing
    incidence of diabetes is expected to be major
    factor driving growth of the market in the near
    future. For instance, according to the World
    Health Organization (WHO), 2016, an estimated 422
    million adults are suffering from diabetes. The
    major spike in incidence of type 2 diabetes over
    the last decade is mainly attributed to
    increasing prevalence of obesity. According to
    the International Diabetes Federation (IDF) Atlas
    2017, global burden of diabetes is affecting more
    than 425 million people, among which one-third
    are older than 65 years of age. Moreover, the
    number of people with diabetes may rise to 629
    million in 2045. Furthermore, 352 million with
    impaired glucose tolerance are at high risk of
    developing diabetes. Furthermore, continuous
    increase in incidence rate of diabetes, owing to
    unhealthy lifegt

6
Market Restraints
  • However, high cost of insulin may restrain growth
    of the market, as patients from low and middle
    countries are unable to afford it. According to
    the Pharmaceutical Care Management Association
    (PCMA) May 2018 report, prices of insulin have
    increased over 10-fold since 1985 and prices have
    exhibited significant rise during the last past
    10 years (2008 to 2018). According to PCMA,
    prices for Humulin/Novolin have increased from
    around US 25 per prescription in 1985 to nearly
    US 300 in 2016. Furthermore, prices for
    long-acting insulins have increased from around
    US 100 per prescription in 2007 to nearly US
    400 in 2016.

7
Key Players
  • Key players operating in human recombinant
    insulin market include Novo Nordisk A/S, Eli
    Lilly and Company, Sanofi S.A., Julphar Gulf
    Pharmaceutical Industries, Biocon Limited, Bioton
    S.A., Gan Lee Pharmaceuticals, Ltd., Zhuhai
    United Laboratories Co., Ltd., Wanbang
    Biopharmaceuticals Co., Ltd., and Dongbao
    Enterprise Group Co., Ltd.

8
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//www.coherentmarketinsights.com
    /market-insight/human-recombinant-insulin-market-1
    797

9
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

10
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

11
  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com